HC Wainwright Reiterates “Buy” Rating for Dyne Therapeutics (NASDAQ:DYN)

HC Wainwright reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a report published on Wednesday, Benzinga reports. The firm currently has a $55.00 price target on the stock.

A number of other research firms have also issued reports on DYN. Piper Sandler increased their target price on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the stock an overweight rating in a report on Tuesday, August 13th. Stifel Nicolaus lifted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the company a buy rating in a report on Friday, August 16th. StockNews.com upgraded Dyne Therapeutics from a sell rating to a hold rating in a report on Friday, August 30th. Oppenheimer reiterated an outperform rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday. Finally, Jefferies Financial Group upped their target price on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the stock a buy rating in a research note on Monday, May 20th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics currently has a consensus rating of Buy and an average price target of $51.40.

Dyne Therapeutics Trading Up 5.7 %

DYN stock opened at $33.76 on Wednesday. The business’s fifty day moving average price is $41.66 and its 200 day moving average price is $32.83. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $47.45. The company has a market capitalization of $2.95 billion, a PE ratio of -8.50 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. Research analysts predict that Dyne Therapeutics will post -2.96 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other news, COO Susanna Gatti High sold 80,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $30.24, for a total transaction of $2,419,200.00. Following the completion of the sale, the chief operating officer now owns 154,062 shares in the company, valued at approximately $4,658,834.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Dyne Therapeutics news, COO Susanna Gatti High sold 80,000 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $30.24, for a total transaction of $2,419,200.00. Following the transaction, the chief operating officer now owns 154,062 shares of the company’s stock, valued at $4,658,834.88. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO John Cox bought 32,000 shares of Dyne Therapeutics stock in a transaction dated Wednesday, September 4th. The stock was purchased at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now directly owns 8,000 shares in the company, valued at approximately $264,320. The disclosure for this purchase can be found here. Insiders sold 163,676 shares of company stock valued at $5,270,510 over the last three months. 20.77% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently modified their holdings of DYN. Concurrent Investment Advisors LLC acquired a new stake in shares of Dyne Therapeutics during the first quarter worth about $573,000. Sei Investments Co. acquired a new stake in Dyne Therapeutics during the 1st quarter worth approximately $693,000. Rafferty Asset Management LLC grew its stake in shares of Dyne Therapeutics by 17.7% in the 4th quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock valued at $2,182,000 after purchasing an additional 24,632 shares during the last quarter. Commodore Capital LP acquired a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $11,970,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Dyne Therapeutics during the first quarter worth approximately $810,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.